98%
921
2 minutes
20
Background: Infections pose a significant risk to immunocompromised individuals, and accurate, efficient diagnosis remain challenging. Current imaging methods like MRI and FDG PET lack pathogen specificity which complicate diagnosis and lead to overuse of antibiotics. Recent data shows that [F]fluoromannitol ([F]FMtl) is sensitive and specific to infection in vivo by exploiting the pathogen-specific mannitol transporter. This work aims to establish a reliable, automated method for producing [F]fluoromannitol to facilitate clinical research studies in human subjects.
Results: This study optimized and automated the radiosynthesis of [F]fluoromannitol ([F]FMtl) on a Trasis AllinOne synthesizer. The 105-minute synthesis achieved an average yield of 11.0% (n=19) with >97% radiochemical purity, and the product remained stable for at least 8 hours. While yield was lower than the previously reported manual method, automation enabled reproducibility and sterility. Process improvements included optimizing evaporation steps and reaction temperature, which significantly increased fluorine incorporation and yield. The process was validated to meet USP <823> regulatory requirements including full QC testing on three consecutive batches.
Conclusions: An automated method for the radiochemical synthesis of [F]fluoromannitol was developed and optimized on a commercially available Trasis AllinOne radiosynthesizer. This method allows for the reliable production and global dissemination of [F]FMtl for use in clinical research trials.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12324609 | PMC |
http://dx.doi.org/10.21203/rs.3.rs-7124066/v1 | DOI Listing |
Background: Infections pose a significant risk to immunocompromised individuals, and accurate, efficient diagnosis remain challenging. Current imaging methods like MRI and FDG PET lack pathogen specificity which complicate diagnosis and lead to overuse of antibiotics. Recent data shows that [F]fluoromannitol ([F]FMtl) is sensitive and specific to infection in vivo by exploiting the pathogen-specific mannitol transporter.
View Article and Find Full Text PDFJ Labelled Comp Radiopharm
July 2025
Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Fluorine-18 labeling of peptides and proteins is typically performed by an indirect labeling method. In this labeling approach, a labeled prosthetic group is prepared first and then conjugated to the proteins and peptides of interest. 6-[F]fluoronicotinic acid-2,3,5,6-tetrafluorophenyl ester is a useful prosthetic group for indirect labeling.
View Article and Find Full Text PDFPharmaceuticals (Basel)
May 2025
Institute of Clinical Physiology, National Research Council, 56124 Pisa, Italy.
: Gliomas, including the most aggressive subtype-glioblastoma multiforme, are brain tumors with an unfavorable prognosis and high mortality. Early diagnosis is essential to improve treatment efficacy. Positron emission tomography PET with O-(2-[F] fluoroethyl)-L-tyrosine ([F]FET) has been supported by clinical studies for its role in diagnosis and monitoring the disease.
View Article and Find Full Text PDFEJNMMI Radiopharm Chem
May 2025
Department of Nuclear Medicine, Molecular Diagnostic Imaging and Therapy, University Hospital of Schleswig-Holstein (UKSH), Campus Kiel, Karl Lennert Cancer Center North, Feld-Str. 21, D-24105, Kiel, Germany.
Background: [F]Fallypride PET has been used to study D2/3 receptor occupancy and density in neuropsychiatric disorders including Huntington's disease (HD) and aging in humans. Nevertheless, the various synthetic methods including those provided by commercial synthesizers for [F]fallypride exhibit a disadvantage concerning the necessity of using a HPLC purification step, which causes difficulties in the automation, leads to long synthesis times and moderate yields. Therefore utilizing the purification step by SPE cartridges is considered highly desirable for future commercialization of radiopharmaceutical cassettes.
View Article and Find Full Text PDFPharmaceuticals (Basel)
January 2025
Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Wilhelm-Johnen-Str., 52428 Jülich, Germany.
The radiotracer [F]JK-PSMA-7, a prostate cancer imaging agent for positron emission tomography (PET), was previously synthesized by indirect radiofluorination using an F-labeled active ester as a prosthetic group, which had to be isolated and purified before it could be linked to the pharmacologically active Lys-urea-Glu motif. Although this procedure could be automated on two-reactor modules like the GE TRACERLab FX2N (FXN) to afford the tracer in modest radiochemical yields (RCY) of 18-25%, it is unsuitable for cassette-based systems with a single reactor. To simplify implementation on an automated synthesis module, the radiosynthesis of [F]JK-PSMA-7 was devised as a one-pot, two-step reaction.
View Article and Find Full Text PDF